At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Abiraterone acetate +1 moredrug
Likely dose
Abiraterone acetate 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
In Brief
A Phase 2 clinical trial evaluating Abiraterone acetate and Prednisone for Prostate Neoplasms. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Neoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionAug 2012
TodayJul 2026
First PostedOct 16, 2007
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.7 years ago
Interventions
Abiraterone acetatedrug
Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Prednisonedrug
Prednisone 5 mg tablet taken orally twice daily